Related Experiment Video
Updated: Aug 9, 2026
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
Membrane cofactor protein and factor I: mutations and transplantation
David Kavanagh1, Timothy H J Goodship
1Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
Insights
Mutations in complement regulators like complement factor H (CFH) and factor I (FI) often lead to kidney failure and poor transplant outcomes in atypical hemolytic uremic syndrome (aHUS). Membrane cofactor protein (MCP) mutations show better transplant success.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- Atypical hemolytic uremic syndrome (aHUS) is associated with genetic defects in complement regulatory proteins.
- Complement factor H (CFH), membrane cofactor protein (MCP), and factor I (FI) are key regulators whose mutations impact complement system function.
Purpose of the Study:
- To investigate the functional consequences of mutations in CFH, MCP, and FI in patients with aHUS.
- To establish genotype-phenotype correlations, particularly regarding end-stage renal failure and transplantation outcomes.
Main Methods:
- Analysis of functional effects of mutations on protein secretion, expression, and regulatory activity.
- Correlation of genetic mutations with clinical phenotypes, including renal failure and transplant graft survival.
Main Results:
- Mutations in CFH, MCP, and FI frequently lead to end-stage renal failure in aHUS patients.
- Transplantation outcomes are poor for CFH and FI mutation carriers (80% graft loss within 2 years) but satisfactory for MCP mutation carriers.
- Combined liver/kidney transplantation has not been successful for CFH mutation patients.
Conclusions:
- Genetic defects in complement regulators significantly influence aHUS prognosis and treatment strategies.
- MCP mutations confer a better prognosis post-transplantation due to its transmembrane nature.
- Future therapies may involve targeted complement inhibition for aHUS management.
Abstract:
Mutations in the genes for three complement regulators-complement factor H (CFH), membrane cofactor protein (MCP), and factor I (IF)-have now been described in patients with atypical HUS. The functional effects of these mutations have been studied in detail and have been shown to affect secretion, expression, and regulatory function. Genotype-phenotype correlations have shown that the majority of patients with CFH, MCP, and FI mutations develop end-stage renal failure. The outcome of transplantation is poor in patients known to have either a CFH or FI mutation, with approximately 80% of patients losing the graft to recurrent disease within 2 years. In contrast, patients known to have only an MCP mutation have a satisfactory transplantation outcome. This is expected because MCP is a transmembrane regulator and allografts will therefore be protected by wild-type MCP. Combined liver/kidney transplantation for patients known to have a CFH mutation has not been successful to date. There is optimism that in the future, targeted complement inhibitors will be of major therapeutic benefit in this condition.
Related Concept Videos
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...